**Table S3. Baseline characteristics of MCL patients receiving BTK inhibitors -containing regimens and standard R-HD-AraC regimens followed by AHCT after propensity score match.**

|  |  |  |
| --- | --- | --- |
| **Characteristic** | **No. (%)** | ***P*** |
| **BTKi induction****(n=28)** | **HD-AraC + AHCT****(n=28)** |
| **Sex** |  |  |  |
| Male | 21 (75%) | 23 (82%) | 0.515 |
| Female | 7 (25%) | 5 (18%) |
| **ECOG PS** |  |  |  |
| 0-1 | 24 (86%) | 25 (89%) | 1.000 |
| ≥2 | 4 (14%) | 3 (11%) |
| **Simplified MIPI** |  |  |  |
|  Low risk | 14 (50%) | 13 (46%) | 0.366 |
| Intermediate risk | 11 (39%) | 8 (29%) |
| High risk | 3 (11%) | 7 (25%) |
| **Blastoid/pleomorphic:** |  |  |  |
| Yes | 26 (93%) | 25 (89%) | 1.000 |
| No | 2 (7%) | 3 (11%) |
| **Ki-67** |  |  |  |
| ≤30% | 15 (54%) | 16 (57%) | 0.788 |
| >30% | 13 (46%) | 12 (43%) |
| **Bone marrow involvement** |  |  |  |
| Yes | 17 (61%) | 16 (57%) | 0.786 |
| No | 11 (39%) | 12 (43%) |
| **Post-induction rituximab maintenance** |  |  |  |
| Yes | 18 (64%) | 12 (43%) | 0.108 |
| No | 10 (36%) | 16 (57%) |

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; MIPI, Mantle Cell Lymphoma International Prognostic Index;